Home Angiogenesis BTK

BTK Inhibitors

Other Angiogenesis Related Inhibitors

Src FGFR HIF Bcr-Abl Syk VDA FLT3 FAK ANGPTL FLT
Cat.No. Product Name Information Product Use Citations Product Validations
E1993 Catadegbrutinib (BGB-16673) Catadegbrutinib (BGB-16673) is an inhibitor of Bruton’s tyrosine kinase (Btk) and can be used in research for the treatment of autoimmune and inflammatory diseases.
S2680 Ibrutinib (PCI-32765) Ibrutinib is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Cell Rep Med, 2025, 6(3):102027
J Allergy Clin Immunol, 2025, 155(2):569-582
Clin Cancer Res, 2025, 10.1158/1078-0432.CCR-25-2907
Verified customer review of Ibrutinib (PCI-32765)
S8116 Acalabrutinib (ACP-196) Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This compound has improved target specificity with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
J Allergy Clin Immunol, 2025, 155(2):569-582
Cancers (Basel), 2025, 17(11)1889
bioRxiv, 2025, 2025.05.20.655210
Verified customer review of Acalabrutinib (ACP-196)
S7173 Spebrutinib (AVL-292) Spebrutinib (AVL-292) is a covalent, orally active, and highly selective BTK inhibitor with IC50 of <0.5 nM, displaying at least 1400-fold selectivity over the other kinases assayed. It is in Phase 1.
oparu, 2023, 10.18725/OPARU-47820
Elife, 2021, 10e66984
American Journal of Physiology-Cell Physiology, 2021, C902-C915
Verified customer review of Spebrutinib (AVL-292)
S8166 tirabrutinib(ONO-4059) hydrochloride Tirabrutinib Hydrochloride (ONO-4059, GS-4059) is a highly potent and selective BTK inhibitor with an IC50 of 2.2 nM.
PLoS One, 2023, 18(8):e0290872
Br J Pharmacol, 2022, 179(11):2754-2770
Am J Physiol Cell Physiol, 2021, 320(5):C902-C915
S7051 CGI1746 CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.
J Allergy Clin Immunol, 2025, 155(2):569-582
Elife, 2020, 9e60470
Am J Transl Res, 2019, 11(7):4139-4150
Verified customer review of CGI1746
S7734 LFM-A13 LFM-A13 is a specific Bruton's tyrosine kinase (BTK) inhibitor with IC50 of 2.5 μM, >100-fold selectivity over other protein kinases including JAK1, JAK2, HCK, EGFR,and IRK.
Br J Pharmacol, 2022, 179(11):2754-2770
Blood Adv, 2020, 4(18):4393-4405
Biochem Pharmacol, 2020, 172:113741
Verified customer review of LFM-A13
S7257 CNX-774 CNX-774 is an irreversible, orally active, and highly selective BTK inhibitor with IC50 of <1 nM.
Cancer Lett, 2023, 552:215981
Br J Pharmacol, 2022, 179(11):2754-2770
Oncol Rep, 2021, 45(5)56
Verified customer review of CNX-774
S8777 Evobrutinib Evobrutinib is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity.
Cancer Res Commun, 2025, 5(9):1621-1630
Brain Pathol, 2024, e13240.
J Leukoc Biol, 2024, qiae160
S8791 Zanubrutinib (BGB-3111) Zanubrutinib is a potent, specific and irreversible BTK inhibitor that has been shown to have a lower off-target inhibitory activity on other kinases, including ITK, JAK3 and EGFR.
Acta Histochemica et Cytochemica, 2025, 93-100
iScience, 2024, 27(10):110862
Blood, 2023, 62-72

Signaling Pathway Map